(RTTNews) - Gilead Sciences, Inc. (GILD), a biopharmaceutical company, announced that it has reached an agreement to acquire investigational oral IL-23R inhibitor program, including lead asset HCXT-2001, from privately held PepStar Therapeutics Ltd.
Publicznie pokazujemy glowna mysl. Utworz darmowe konto, aby czytac caly artykul, zapisac go, omowic i polaczyc z kontekstem rynkowym oraz OSINT.